EMA provides more advice on upcoming pharmacovigilance annual fees

These payments cover work by EMA on detection, assessment, understanding and preventing adverse effects

Additional advice has been released by the European Medicines Agency (EMA) on annual fees charged to European Union pharmaceutical companies from 1 July for the Agency’s pharmacovigilance activities regarding nationally authorised medicines. These pay for EMA’s work on detection, assessment, understanding and prevention of adverse effects.

EMA says companies should review the agency’s product information, which determines fees.